Related references
Note: Only part of the references are listed.Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study
Jun Ishigooka et al.
JOURNAL OF AFFECTIVE DISORDERS (2021)
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Mark R. Libowitz et al.
FRONTIERS IN PSYCHIATRY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Use of antipsychotics in Denmark 1997-2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses
M. Hojlund et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2021)
Polypharmacy in schizophrenia
Lone Baandrup
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2020)
Making Sense of ... the Microbiome in Psychiatry
Thomaz F. S. Bastiaanssen et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects
Kari M. Ersland et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
Tali Bretler et al.
BMC MEDICINE (2019)
Reversibility of psychotropic medication induced weight gain among children and adolescents with bipolar disorders
Navneet Upadhyay et al.
PSYCHIATRY RESEARCH (2019)
Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis
Kentaro Matsui et al.
SCHIZOPHRENIA RESEARCH (2019)
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission The STOP-PD II Randomized Clinical Trial
Alastair J. Flint et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Lifestyle Interventions for Weight Management in People with Serious Mental Illness: A Systematic Review with Meta-Analysis, Trial Sequential Analysis, and Meta-Regression Analysis Exploring the Mediators and Moderators of Treatment Effects
Helene Speyer et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Diana Grajales et al.
CELLS (2019)
Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians' choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study
Christoph U. Correll et al.
CNS SPECTRUMS (2019)
Model-Guided Antipsychotic Dose Reduction in Schizophrenia A Pilot, Single-Blind Randomized Controlled Trial
Chisa Ozawa et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
Maintenance of Lost Weight and Long-Term Management of Obesity
Kevin D. Hall et al.
MEDICAL CLINICS OF NORTH AMERICA (2018)
Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis
Meghan Bowtell et al.
SCHIZOPHRENIA RESEARCH (2018)
Management of common adverse effects of antipsychotic medications
T. Scott Stroup et al.
WORLD PSYCHIATRY (2018)
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
W. Wolfgang Fleischhacker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2017)
Improved Metabolic and Psychiatric Outcomes with Discontinuation of Atypical Antipsychotics in Youth Hospitalized in a State Psychiatric Facility
Leslie Hulvershorn et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2017)
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study
Joseph R. Calabrese et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial
L. N. Yatham et al.
MOLECULAR PSYCHIATRY (2016)
Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine
Adam Wysokinski et al.
NORDIC JOURNAL OF PSYCHIATRY (2016)
Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available
Miguel A. Hernan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2016)
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study
Peter J. Weiden et al.
CNS DRUGS (2016)
Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder
Young Sup Woo et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2016)
BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment
Stephen J. Cooper et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
National trends in off-label use of atypical antipsychotics in children and adolescents in the United States
Minji Sohn et al.
MEDICINE (2016)
Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Suresh Durgam et al.
SCHIZOPHRENIA RESEARCH (2016)
The CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesity
Helene Speyer et al.
WORLD PSYCHIATRY (2016)
Plea for routinely presenting prediction intervals in meta-analysis
Joanna IntHout et al.
BMJ OPEN (2016)
Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia
Hiroyoshi Takeuchi et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2015)
Fast Versus Slow Strategy of Switching Patients With Schizophrenia to Aripiprazole From Other Antipsychotics
Tzung-Jeng Hwang et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2015)
Abstracts for the 15th International Congress on Schizophrenia Research (ICOSR)
SCHIZOPHRENIA BULLETIN (2015)
Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study
Takashi Tsuboi et al.
SCHIZOPHRENIA RESEARCH (2015)
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia A Prospective Dopamine D2/3 Receptor Occupancy Study
Ariel Graff-Guerrero et al.
JAMA PSYCHIATRY (2015)
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis
D. M. Taylor et al.
ACTA PSYCHIATRICA SCANDINAVICA (2014)
Cardiometabolic Outcomes in Children and Adolescents Following Discontinuation of Long-Term Risperidone Treatment
Chadi A. Calarge et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2014)
Lack of Effect of Risperidone or Olanzapine Dose Reduction on Metabolic Parameters, Prolactin, and Corrected QT Interval in Stable Patients With Schizophrenia
Hiroyoshi Takeuchi et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
Elizabeth Brunner et al.
NEUROPSYCHOPHARMACOLOGY (2014)
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Maarten Bak et al.
PLOS ONE (2014)
Relapse prevention study of paliperidone eltended-release tablets in Chinese patients with schizophrenia
Qing Rui et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder
Allan H. Young et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2014)
Management of psychosis and schizophrenia in adults: summary of updated NICE guidance
Elizabeth Kuipers et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Decisional capacity: toward an inclusionary approach
Carmelle Peisah et al.
INTERNATIONAL PSYCHOGERIATRICS (2013)
Effects of Controlled Discontinuation of Long-Term Used Antipsychotics on Weight and Metabolic Parameters in Individuals With Intellectual Disability
Gerda de Kuijper et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized controlled trial
T. Scott Stroup et al.
SCHIZOPHRENIA RESEARCH (2013)
Interventions to reduce antipsychotic polypharmacy: A systematic review
Hideaki Tani et al.
SCHIZOPHRENIA RESEARCH (2013)
Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)
Berit X. Carlson et al.
BIPOLAR DISORDERS (2012)
A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode
Joris Berwaerts et al.
JOURNAL OF AFFECTIVE DISORDERS (2012)
Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients With Schizophrenia: A 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study
Yuejin Chen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Stefan Leucht et al.
LANCET (2012)
Maintenance treatment with antipsychotic drugs for schizophrenia
Stefan Leucht et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study
Ronald Marcus et al.
BIPOLAR DISORDERS (2011)
Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia
Yutaro Suzuki et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2011)
A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Continuation of Quetiapine Versus Switching to Placebo or Lithium for Maintenance Treatment of Bipolar I Disorder (Trial 144: A Randomized Controlled Study)
Richard H. Weisler et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Chuan-Yue Wang et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Olanzapine Long-Acting Injection: A 24-Week, Randomized, Double-Blind Trial of Maintenance Treatment in Patients With Schizophrenia
John M. Kane et al.
AMERICAN JOURNAL OF PSYCHIATRY (2010)
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
Jorge A. Quiroz et al.
BIOLOGICAL PSYCHIATRY (2010)
EFFICACY AND TOLERABILITY OF EXTENDED RELEASE QUETIAPINE FUMARATE MONOTHERAPY AS MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Michael Liebowitz et al.
DEPRESSION AND ANXIETY (2010)
Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study
Hiroyoshi Takeuchi et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2010)
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial
Eric Y. H. Chen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127)
Trisha Suppes et al.
AMERICAN JOURNAL OF PSYCHIATRY (2009)
A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently
Wayne Macfadden et al.
BIPOLAR DISORDERS (2009)
Effectiveness of Switching to Aripiprazole From Atypical Antipsychotics in Patients With Schizophrenia
Sung-Wan Kim et al.
CLINICAL NEUROPHARMACOLOGY (2009)
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: Results of a randomized, open label study
Chi-Un Pae et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Olanzapine Plasma Concentrations After Treatment With 10, 20, and 40 mg/d in Patients With Schizophrenia An Analysis of Correlations With Efficacy, Weight Gain, and Prolactin Concentration
Leslie Citrome et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Switching to Aripiprazole in Outpatients with Schizophrenia Experiencing Insufficient Efficacy and/or Safety/Tolerability Issues with Risperidone: A Randomized, Multicentre, Open-label Study
V. Ryckmans et al.
PHARMACOPSYCHIATRY (2009)
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole
S. G. Schorr et al.
ACTA PSYCHIATRICA SCANDINAVICA (2008)
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression
George S. Alexopoulos et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Strategies of treatment with olanzapine in schizophrenic patients during stable phase: Results of a pilot study
Frederic Rouillon et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine
John W. Newcomer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report
Saddichha Sahoo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo
Paul E. Keck et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain - A pilot study
Sun H. Kim et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: A retrospective chart review
Ronald D. Spurling et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia - A randomized, double-blind, placebo-controlled study
Michelle Kramer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation
Mark Hyman Rapaport et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Statistics notes - The cost of dichotomising continuous variables
DG Altman et al.
BRITISH MEDICAL JOURNAL (2006)
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine
M Tohen et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Reasons for switching between antipsychotics in daily clinical practice
GWK Hugenholtz et al.
PHARMACOPSYCHIATRY (2005)
Diabetes associated with atypical antipsychotic treatment may be severe but reversible: Case report
CRM Dibben et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE (2005)
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
M Tohen et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
CM Beasley et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2003)
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
DE Casey et al.
PSYCHOPHARMACOLOGY (2003)
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
SJ Cooper et al.
PSYCHOPHARMACOLOGY (2000)
Share Paper
